A recent study conducted by the Institute of Life Sciences at Swansea University and EKF Molecular Diagnostics found that EKF Diagnostics’ PointMan DNA enrichment technology could have applications in future cancer testing and treatment. The study analyzed gene mutations in blood from samples archived in the Wales Cancer Bank. Using PointMan technology, researchers assessed whole blood of patients diagnosed with metastatic melanoma to identify gene mutations associated with response to drug treatment. Results observed for mutations in the gene BRAF were consistent with the formalin-fixed paraffin embedded (FFPE) tissue samples and later confirmed by DNA sequencing. EKF’s other PointMan DNA enrichment products include, KRAS, EGFR, NRAS, and JAK2. For more information, visit EKF Diagnostics.